medwireNews: Analyses of metabolic, biomarker, and other outcomes from the DAPA-HF trial presented at the 55th EASD Annual Meeting in Barcelona, Spain, provide additional insights into the efficacy of dapagliflozin in patients with heart failure (HF).
Click through for our report on the main results from DAPA-HF
The investigators demonstrated that the sodium-glucose cotransporter 2 inhibitor may have differential effects in HF patients with and without type 2 diabetes. For instance, in those with diabetes, the impact of dapagliflozin on glycated hemoglobin (HbA1c), bodyweight, and blood pressure was consistent with that shown in previous trials, whereas in HF patients without diabetes, dapagliflozin had “no substantive effects” on HbA1c or bodyweight.
“These data support the notion that the [cardiovascular] benefits of this diabetes medication likely [have] nothing to do with its effects on diabetes,” said presenting author Silvio Inzucchi (Yale University School of Medicine, New Haven, Connecticut, USA).
And in an exploratory biomarker analysis of DAPA-HF, dapagliflozin significantly reduced N-terminal pro b-type natriuretic peptide (NT-proBNP) levels, in contrast to the findings from the smaller DEFINE-HF trial, which demonstrated no significant impact of dapagliflozin on NT-proBNP levels over a shorter duration of follow-up.
Specifically, in DAPA-HF, Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA) reported that median NT-proBNP levels after 8 months of treatment were significantly lower among participants treated with dapagliflozin 10 mg/day compared with those given placebo, with a between-group difference of 303 pg/mL.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group
EASD 2019; Barcelona, Spain: 16–20 September